These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11959188)

  • 21. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation.
    Kim CK; Song JH; Kim SM; Peck KR; Oh W; Huh W; Kim YG; Kim SJ; Joh JW; Lee NY; Park CG; Hwang ES; Cha CY; Oh HY
    Transplantation; 2003 Jun; 75(12):2151-5. PubMed ID: 12829929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients.
    Gerna G; Sarasini A; Lilleri D; Percivalle E; Torsellini M; Baldanti F; Revello MG
    J Infect Dis; 2003 Dec; 188(11):1639-47. PubMed ID: 14639533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New immunosuppressive regimens and cytomegalovirus infection after kidney transplantation: a retrospective study.
    Côté I; Deschêsnes L; de Cotret PR; Lachance JG; Noël R; Isenring P; Houde I
    Transplant Proc; 2001; 33(7-8):3626-9. PubMed ID: 11750540
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.
    Saitoh A; Sakamoto S; Fukuda A; Shigeta T; Kakiuchi T; Kamiyama S; Katsuta T; Shoji K; Ogimi C; Kasahara M
    Transplantation; 2011 Oct; 92(8):930-5. PubMed ID: 21941226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The antigenemia test for cytomegalovirus].
    Pérez JL; Salvà J; Niubó J
    Enferm Infecc Microbiol Clin; 1994 May; 12(5):251-61. PubMed ID: 8049289
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
    Greijer AE; Verschuuren EA; Dekkers CA; Adriaanse HM; van der Bij W; The TH; Middeldorp JM
    J Infect Dis; 2001 Aug; 184(3):247-55. PubMed ID: 11443549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus antigenemia as a marker for antiviral therapy after heart transplantation.
    Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayr T; Prenner G; Hipmair G; Grasser B; Freigassner M
    J Heart Lung Transplant; 1996 Mar; 15(3):314-5. PubMed ID: 8777216
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytomegalovirus antigenemia assay: identification of the viral antigen as the lower matrix protein pp65.
    Grefte JM; van der Gun BT; Schmolke S; van der Giessen M; van Son WJ; Plachter B; Jahn G; The TH
    J Infect Dis; 1992 Sep; 166(3):683-4. PubMed ID: 1323626
    [No Abstract]   [Full Text] [Related]  

  • 31. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
    J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies.
    Iberer F; Halwachs-Baumann G; Rödl S; Pleisnitzer A; Wasler A; Auer T; Petutschnigg B; Müller H; Tscheliessnigg K; Wilders-Truschnig M
    J Heart Lung Transplant; 1994; 13(3):405-11. PubMed ID: 8061015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preemptive treatment with oral ganciclovir for pediatric renal transplantation.
    Melgosa Hijosa M; García Meseguer C; Peña Garcia P; Alonso Melgar A; Espinosa Román L; Peña Carrión A; Navarro Torres M
    Clin Nephrol; 2004 Apr; 61(4):246-52. PubMed ID: 15125030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
    Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
    Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intestinal infection by cytomegalovirus in kidney transplantation: diagnostic difficulty in the course of mycophenolate mofetil therapy].
    Mugnani G; Bergami M; Lazzarotto T; Bedani PL
    G Ital Nefrol; 2002; 19(4):483-4. PubMed ID: 12378698
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of pp65 antigenemia, quantitative PCR and DNA hybrid capture for detection of cytomegalovirus in transplant recipients and AIDS patients.
    Mhiri L; Kaabi B; Houimel M; Arrouji Z; Slim A
    J Virol Methods; 2007 Jul; 143(1):23-8. PubMed ID: 17336402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
    Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
    Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.